
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 49
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT00096876 | A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients | ||
NCT00870974 | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions | ||
NCT00427674 | Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients | ||
NCT01268020 | Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC | ||
NCT00096720 | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease | ||
NCT00970229 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | ||
NCT00556660 | Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects | ||
NCT00605046 | Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects | ||
NCT02103894 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | ||
NCT00132626 | Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome | ||
NCT00480701 | Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease | ||
NCT00287248 | Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain | ||
NCT00470925 | Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects | ||
NCT00397696 | Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease | ||
NCT02370524 | Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease | ||
NCT00439010 | Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects | ||
NCT00129181 | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | ||
NCT00612872 | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects | ||
NCT00117195 | A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease | ||
NCT01141023 | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | ||
NCT00315250 | Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease | ||
NCT00456417 | Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects | ||
NCT00657813 | Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition | ||
NCT00117819 | A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease | ||
NCT00870519 | Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects | ||
NCT00354003 | The Study of the Impact of Disclosing Imaging Study Information to Trial Participants | ||
NCT00556764 | Development of Cognitive Assessment Tools in Parkinson Disease | ||
NCT01462708 | Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects | ||
NCT01000870 | Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513 | ||
NCT00448799 | Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls | ||
NCT00387075 | A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease | ||
NCT00605059 | Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects | ||
NCT01217021 | Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 | ||
NCT00134784 | Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression | ||
NCT04906590 | PPMI Tau PET Imaging | ||
NCT00129675 | Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty | ||
NCT00886951 | Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease | ||
NCT00404170 | Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease | ||
NCT01209156 | Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions | ||
NCT01028209 | Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions | ||
NCT04477785 | PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | ||
NCT01461109 | Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls | ||
NCT00970333 | Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions | ||
NCT01767493 | Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients | ||
NCT00397228 | ALTROPANE® SPECT Imaging in Patients With Parkinson Disease | ||
NCT01461083 | Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a | ||
NCT00968097 | Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition | ||
NCT00316797 | Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects | ||
NCT00273351 | Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families |